Shanghai Henlius Biotech Anti-CD73 Antibody Patent US12606633B2
Summary
The USPTO granted Patent US12606633B2 to Shanghai Henlius Biotech, Inc. on April 21, 2026, covering anti-CD73 antibodies, variants, and antigen binding fragments that bind human CD73 with high affinity and suppress enzymatic activity. The patent includes 17 claims and covers isolated nucleic acid molecules, expression vectors, host cells, and related pharmaceutical compositions for treating subjects.
What changed
The USPTO granted Patent US12606633B2 to Shanghai Henlius Biotech, Inc., covering methods and compositions for anti-CD73 antibodies and variants. The patent specifies antibodies that bind human CD73 with high affinity, suppress enzymatic activity, and optionally induce CD73 internalization, along with related nucleic acid molecules, expression vectors, host cells, and pharmaceutical compositions.
Pharmaceutical and biotechnology companies developing CD73-targeted therapeutics should review this patent to assess potential freedom-to-operate implications. The patent's broad claim scope covering antibody variants, fragments, and associated methods may affect competing product development strategies in the immuno-oncology space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and compositions for anti-CD73 antibodies and variants
Grant US12606633B2 Kind: B2 Apr 21, 2026
Assignee
SHANGHAI HENLIUS BIOTECH, INC.
Inventors
Wei-Dong Jiang, I-yin Chen, Chi-Ling Tseng
Abstract
Provided are anti-CD73 antibodies, variants, and antigen binding fragments thereof. The antibodies, the variants, and the antigen binding fragments thereof bind to human CD73 with high affinity, and suppress the enzymatic activity of CD73, and optionally induce CD73 internalization. Further provided are isolated nucleic acid molecules encoding the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof, and a related expression vector and a host cell. Provided is a method for preparing the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof. Further provided are related pharmaceutical compositions and a method for using said pharmaceutical compositions in treating a subject.
CPC Classifications
C07K 16/2896 C07K 2317/31 C07K 2317/33 C07K 2317/565 C07K 2317/77 C07K 2317/52 C07K 2317/55 C07K 2317/76 C07K 2317/92 C07K 16/40 C07K 2317/56 A61K 39/3955 A61K 45/06 A61K 47/6849 A61K 2039/505 A61P 35/00 G01N 33/57492
Filing Date
2022-01-25
Application No.
17584258
Claims
17
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.